Health & Fitness – Genzyme reported today that a preliminary analysis of data from an ongoing open-label Phase 2 clinical trial of its investigational oral therapy Genz-112638 showed that the compound produced a meaningful impact on key clinical manifestations of Gaucher disease.
Not a member? Sign-up today!
About Propeller | Frequently Asked Questions | Help
© 2003-2008 Propeller. All Rights Reserved. Terms of Use | Privacy Policy
0)
Vote